Equity Overview
Price & Market Data
Price: $4.68
Daily Change: +$0.23 / 4.91%
Range: $4.49 - $4.80
Market Cap: $34,191,144
Volume: 18,474
Performance Metrics
1 Week: 6.61%
1 Month: 10.90%
3 Months: -18.63%
6 Months: -32.66%
1 Year: -30.67%
YTD: -30.36%
Company Details
Employees: 55
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.